Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen and Servier announces heart failure drug partnership

Amgen and Servier announces heart failure drug partnership

11th July 2013

Amgen has announced a new cardiovascular disease product collaboration agreement with fellow healthcare company Servier.

Under the terms of the deal, Amgen will gain US commercial rights to Procoralan, Servier's novel oral therapy for chronic heart failure and stable angina among people with elevated heart rates, as well as the developmental drug S38844.

In return, Servier will receive European rights for the commercialisation of omecamtiv mecarbil, an activator of cardiac myosin that is currently being tested for potential applications in the treatment of heart failure in patients with systolic dysfunction.

Both companies will be able to exercise their respective options for the investigational therapies up to completion of certain phase II studies.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "We value Servier's extensive experience in cardiovascular disease and look forward to working with them as Amgen continues to build our presence in this area."

During the first quarter of 2013, Amgen achieved a five percent year-on-year increase in sales revenues, thanks to rising demand for drugs such as Enbrel, Xgeva and Prolia.ADNFCR-8000103-ID-801610917-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.